Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

NCT00419536 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone Refractory Prostate Cancer Disease

Interventions

DRUG: LBH589

Sponsor

Novartis Pharmaceuticals